1. Ades L, Sanz MA, Chevret S et al (2008) Treatment of newly diagnosed acute promyelocytic leukemia (APL): a comparison of French-Belgian-Swiss and PETHEMA results. Blood 111:1078–1084
2. Agrawal S, Hofmann W-K, Tidow N et al (2007) The C/EBP{delta} tumor suppressor is silenced by hypermethylation in acute myeloid leukemia. Blood 109:3895–3905
3. Alcalay M, Tiacci E, Bergomas R et al (2005) Acute myeloid leukemia bearing cytoplasmic nucleophosmin (NPMc + AML) shows a distinct gene expression profile characterized by up-regulation of genes involved in stem-cell maintenance. Blood 106:899–902
4. Amadori S, Suciu S, Stasi R et al (2005) Gemtuzumab ozogamicin (Mylotarg) as single-agent treatment for frail patients 61 years of age and older with acute myeloid leukemia: final results of AML-15B, a phase 2 study of the European organisation for research and treatment of cancer and Gruppo Italiano Malattie Ematologiche dell’Adulto leukemia groups. Leukemia 19:1768–1773
5. An WG, Schulte TW, Neckers LM (2000) The heat shock protein 90 antagonist geldanamycin alters chaperone association with p210bcr-abl and v-src proteins before their degradation by the proteasome. Cell Growth Differ 11:355–360